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Introduction: Porous silicon (PSi) nanoparticles are capable of delivering therapeutic payloads providing 
targeted delivery and sustained release of the payloads. In this work we describe the development and 
proof-of-concept in vivo evaluation of thermally hydrocarbonized porous silicon (PSi) nanoparticles that are 
implanted with radioactive 155Tb atoms and coated with red blood cell (RBC) membrane (155Tb-THCPSi). The 
developed nanocomposites can be utilized as an intravenous delivery platform for theranostic 
radionuclides. 
Methods: THCPSi thin films were implanted with 155Dy ions that decay to 155Tb at the ISOLDE radioactive 
ion-beam (RIB) facility at CERN. The films were processed to nanoparticles by ball-milling and sonication, 
and subsequently coated with either a solid lipid and RBC membrane or solely with RBC membrane. The 
nanocomposites were evaluated in vitro for stability and in vivo for circulation half-life and ex vivo for 
biodistribution in Balb/c mice. 
Results: Nanoporous THCPSi films were successfully implanted with 155Tb and processed to coated 
nanoparticles. The in vitro stability of the particles in plasma and buffer solutions was not significantly 
different between the particle types, and therefore the RBC membrane coated particles with less laborious 
processing method were chosen for the biological evaluation. The RBC membrane coating enhanced 
significantly the blood half-life compared to bare THCPSi particles. In the ex vivo biodistribution study a 
pronounced accumulation to the spleen was found, with lower uptake in the liver and a minor uptake in 
the lung, gall bladder and bone marrow. 
Conclusions: We have demonstrated, using 155Tb RIB-implanted PSi nanoparticles coated with mouse RBC 
membranes, the feasibility of using such a theranostic nanosystem for the delivery of RIB based 










Advances in Knowledge and Implications for Patient Care: For the first time, the RIB implantation technique 
has been utilized to produce PSi nanoparticle with a surface modified for better persistence in circulation. 
When optimized, these particles could be used in targeted radionuclide therapy with a combination of 
chemotherapeutic payload within the PSi structure. 
Abbreviated title: 155Tb delivery with porous silicon nanoparticles 
Keywords: Terbium-155, radioactive ion beam, porous silicon, red blood cell membrane, circulation time, 
theranostics 
1. Introduction 
Porous silicon (PSi) has gained over the past two decades widespread interest as a nanoscale drug delivery 
system due to its capability to deliver a multitude of poorly soluble therapeutics[1-4], biological drugs[5-8] 
and even secondary nanomaterial payloads[9], providing enhanced biological barrier permeation, targeted 
delivery and sustained release. It has demonstrated high biocompatibility and safety[10-13] in all 
administration routes with biodegradation into silicic acid excreted in urine for facile elimination from the 
body[14, 15]. Fabrication of porous silicon can be done using various top-down and bottom-up approaches 
which provide a wide selection of pore morphologies and structures depending on the method[16]. A 
common method of fabrication is through electrochemical anodization of crystalline silicon wafers in 
aqueous hydrofluoric acid (HF) solutions where the porosity, pore size and thickness of the porous layer 
can be easily controlled by the composition of the etching media and the applied anodization current[17]. 
Recently, bottom-up synthetic approaches resulting in PSi nanoparticles of a controlled spherical geometry 
have been reported, and biomedical applications such as drug delivery and immunotherapy employing 
spherical nanoparticles produced using the high‐shear microfluidization techniques are becoming prevalent 
over the ones using quasi-spherical particles produced by ultrasonication[18]. The freshly-etched, or “as-
anodized” surface of PSi is highly reactive due to the presence of surface hydrides[19], and consequently, 










for further surface modification to tailor the drug delivery properties[20, 21] and for the conjugation of 
imaging labels[1, 10, 22, 23] and targeting moieties[24-26]. The surface modifications used for the 
passivation and functionalization of the fresh, hydrogen-terminated PSi surface include thermal 
oxidation[27], thermal carbonization and thermal hydrocarbonization[28, 29], and various techniques of 
hydrosilylation providing an avenue to for example carboxylic acid, amine, and alkyne terminated PSi[30-
32]. The modification of interest for this work is thermal hydrocarbonization, which renders the PSi surface 
hydrophobic and amenable to subsequent encapsulation for example into a solid lipid nanoparticle for 
tailoring of the degradation kinetics[33], or into isolated mouse red blood cell membrane for evasion of 
immune recognition and prolonged residence in circulation[34].   
Nanoscale drug delivery systems are intensely investigated for improving the effectiveness and safety of 
drug therapy in cancer. However, many nanosystems fail to provide significant therapeutic advantage due 
to suboptimal in vivo performance including short circulation time, immune recognition, and poor tumor 
accumulation and penetration[35]. There has been increasing interest in new technologies to prolong 
nanoparticle circulation time in human body, with polymer encapsulation (typically PEGylation), liposomal 
drug carriers and serum albumin conjugates being the most widely applied and clinically translated[36]. 
Recently however, cell membrane-derived drug carriers have emerged as natural, biocompatible, and long-
circulating options for drug delivery and immunotherapy[37, 38]. Red blood cells (RBC) express on their 
surface CD47, which is a trans-membrane protein signaling to macrophages not to phagocytose them[39]. 
RBC-membrane camouflaged nanoparticles (NP) have demonstrated to possess a significantly improved 
capability for evasion from the mononuclear phagocytic system (MPS) recognition compared to the current 
gold standard of PEGylated NPs. Furthermore, even though PEGylation results in an extended NP 
circulation time initially, a second injection of the same formulation often leads to much more rapid 
clearance compared to the first injection due to an immune response to the PEGylated particles[40]. 
The use of theranostic matched isotopic multiplets has gained increasing interest in radiotherapy. A 
theranostic multiplet consists of one element having isotopes with different medically relevant radiative 










(+, t1/2 = 17.5 h) and 
155Tb (EC, t1/2 = 5.32 d) are suitable for imaging (positron emission tomography (PET) 
and single photon emission computed tomography (SPECT), respectively) and the isotopes 149Tb (/+, t1/2 = 
4.12 h) and 161Tb (-, t1/2 = 6.89 d) have a potential to be used for therapy (through alpha and 
beta/CE/Auger electron emission, respectively)[42].   Neutron-rich 161Tb is produced by irradiation of 
enriched 160Gd targets in high flux reactors. Short-lived 161Gd produced by thermal neutron capture decays 
quickly (T1/2=3.6 min) to 
161Tb. Subsequently n.c.a. 161Tb is radiochemically separated from the Gd 
targets[43, 44]. Similar to commercially available n.c.a. 177Lu this method can be upscaled to TBq activities 
per batch. On the other hand, the neutron-deficient Tb isotopes were so far mainly produced by GeV 
proton induced spallation reactions combined with on-line mass separation at the ISOLDE facility at 
CERN[45] and collected as radioactive ion beams (RIB), a method also used here and described in more 
detail in section 2.2. Now a dedicated facility, MEDICIS at CERN[46], is under commissioning to make these 
isotopes available more frequently. Production of 152Tb and 155Tb can also be envisaged by (p,n) reactions at 
medical cyclotrons combined with a radiochemical Tb/Gd separation (similar to n.c.a. 161Tb production), 
provided sufficiently enriched 152Gd and 155Gd targets become available[47].  
Previously, we have demonstrated thermally hydrocarbonized porous silicon (THCPSi) as a suitable 
platform for implantation of RIB-based radiolantanoids using 159Dy[48].  Herein, we describe the 
development and proof-of-concept in vivo evaluation of thermally hydrocarbonized PSi nanoparticles that 
are implanted with radioactive 155Tb atoms and coated with RBC membrane as an intravenous delivery 
platform for the theranostic quadruplet of terbium, as well as for other RIB based nuclei.  In contrast to 
conventional radiolabeling methods, the RIB implantation process is independent on the chemistry of the 
radionuclide, and therefore the radiolabel can be easily changed to any radionuclide that can be obtained 
from a RIB facility.  To this end, PSi offers several advantages including the possibility for RIB implantation 
into free-standing films which can be post-processed to nanoparticles, the possibility to add a secondary 
chemotherapeutic payload to the porous network of PSi, as well as the targeting and stealth capability 
endowed by the RBC encapsulation. THCPSi free-standing films were implanted with a radioactive ion beam 










Balb/c mouse RBC membranes with and without a solid lipid (glyceryl monostearate/L--phosphatidyl 
choline/polyvinyl alcohol/PEG) coating prepared using a solid-in-oil-in-water (S/O/W) emulsion method. 
We report the in vitro stability of the 155Tb-nanocomposites in physiological media with the determination 
of the circulation half-life and ex vivo biodistribution after a single intravenous administration to healthy 
female Balb/c mice.   
2. Experimental 
2.1. Production of THCPSi 
The THCPSi thin films were fabricated by electrochemically anodizing boron-doped p+-type Si(100) wafers 
of 0.01-0.02 Ωcm resistivity in a 1:1 (v/v) HF (38 %)–ethanol electrolyte using a pulsed etching profile, 
producing alternating high and low porosity layers. After the total thickness of the porous layer had 
reached ca. 40 µm, the layer was lifted off the wafer by increasing the etching current into electropolishing 
region. The obtained multilayer PSi thin films were then thermally hydrocarbonized at 500 °C with 
acetylene using a previously described method[21].  
2.2. Radionuclide implantation and depth profile 
Two 40-µm thick THCPSi films ( = 1 cm) were implanted at the ISOLDE ion-beam facility at CERN with 
155Dy ions that decay (t1/2 = 9.9 h) to 
155Tb. A 1.4 GeV proton beam impinged on a primary tantalum target. 
Radioactive lanthanoid nuclides were produced in the tantalum foil target (94 g/cm2 Ta)  through spallation 
reactions, thermally released from the 2000 C hot target, ionized in a 2000 C hot tungsten cavity, 
accelerated with a voltage of 30 kV and mass-separated with the magnetic sector field of the ISOLDE 
General Purpose Separator[49]. The thermal ionization of dysprosium was significantly enhanced with the 
resonance ionization laser ion source[50, 51] tuned to dysprosium, yielding a radioactive ion beam of 155Dy 
with an intensity of about 1010 particles per second. Two THCPSi films were mounted on iron holders and 
placed in a collection chamber on the high-mass side of the general-purpose separator. 155Dy ions were 
implanted into the mesoporous layer one film after another over a time of 85 and 45 minutes, respectively. 
The samples were implanted also with 139Ce (EC, t1/2 = 137.6 d) as an impurity, resulting as a molecular side 










To characterize the implantation process, a separate run at ISOLDE was performed in order to estimate the 
implantation depth of the parent activity 155Dy. A beam of 155Dy with an energy of 50 keV was implanted 
into a 40-µm thick THCPSi film. After that, the film was exposed to a successive ion-beam etching to 
remove layers of material from the top of the film and deposit them on a moving tape. Altogether 30 tape 
samples were produced by etching, first ten in 10 nm steps, next ten in 50 nm steps and last ten in 1 µm 
steps. The tape was sectioned and from each section a gamma-ray intensity was measured using a Hidex 
Automatic Gamma Counter with the energy window set at the characteristic gamma-ray peak of the 
daughter activity 155Tb. For calibrating the total depth reached by the etching process, a profilometer (KLA-
Tencorin P-15) was used. In order to understand the depth profile of the sputtering results, the profile was 
simulated using SRIM – The Stopping and Range of Ions in Matter software package[52].  The penetration 
of 30 keV 155Dy ions was simulated in solid and in 70% porous silicon, resulting in the depth profiles of 155Dy 
in the simulated materials.   
It has to be stressed that in the present method the primary production target and the secondary 
implantation target are completely separate. The production target (here tantalum) is irradiated by GeV 
proton beams to induce spallation reactions and is located in a heavily shielded area. In contrast the 
implantation target (here THCPSi film) is easily accessible in a dedicated vacuum chamber where it gets ion-
implanted with a mass-separated low-energy radioactive ion beam. Hence, type and geometry of either 
target can be chosen and optimized completely independently which gives this method a particular 
flexibility. Unlike other radiolabeling methods where the sample itself is activated by neutron or charged 
particle irradiation here only the radioisotope of interest or possible (pseudo-)isobars are implanted but no 
other disturbing radionuclides are generated during the implantation (heavy ions of 30 keV are far too slow 
to overcome the Coulomb barrier; several orders of magnitude higher energies would be required to 
induce nuclear reactions). 
 










The implanted films were transported to the University of Helsinki for post-implantation processing. The 
activity of the films was first measured by using a HPGe detector. After that, the films were extracted from 
the holders and placed into a small glass ampoule with 1 mm ZrO2 beads.  To enhance the milling process, a 
piece of inactive THCPSi film was added to the ampoule.  The ampoule was filled with dec-1-ene and milled 
with a planetary ball mill (Fritsch Pulverisette 6) using an in-house made adapter.  After milling, the milled 
slurry of THCPSi in dec-1-ene was sonicated with a tip sonicator (tip  = 3 mm, QSonica, Newtown, CT, 
USA).  After that, the dec-1-ene was replaced with ethanol using centrifugation. Particle size selection was 
done by centrifugation in ethanol dispersions.  
A reference batch of inactive THCPSi nanoparticles was made using the same methods from non-implanted 
THCPSi films for physical characterization of the produced nanoparticles. Specific surface area and pore 
volume were calculated from results of nitrogen sorption at -196°C (Tristar 3000, Micromeritics Inc., 
Norcross, USA) using the Brunauer-Emmett-Teller (BET) method and taking the total adsorbed amount of 
N2 at a relative pressure (p/p0) of 0.95. The porous structure was imaged with scanning electron microscopy 
using a field-emission SEM (Apreo S, Thermo Scientific, Eindhoven, The Netherlands).  High-angle annular 
dark-field (HAADF) images were taken using a STEM detector attached to the field-emission SEM.  Inactive 
coated nanoparticle samples were imaged using transmission electron microscopy (TEM, JEM-1400, JEOL, 
Tokyo, Japan), which was operated at 80 kV in a bright-field mode. The hydrodynamic diameter (Z-average) 
and polydispersity index (PdI) were measured in ethanol by dynamic light scattering (DLS) using a Malvern 
Zetasizer Nano ZS instrument (Malvern Panalytical, Malvern, UK).  The role of DLS was to provide rapid size 
class information during the formulation process. The same instrument was used to measure the zeta 
potential of the nanoparticles in 10 mM phosphate-buffered saline (PBS), pH 7.4 based on electrophoretic 
mobility of the nanoparticles.  
2.3.1. Solid lipid coating 
The solid lipid (SL) coating of [155Tb]THCPSi nanoparticles was carried out using a solid-in-oil-in-water 










nanoparticles, glyceryl monostearate (100 mg) and L--phosphatidyl choline (40 mg) were dispersed in 5 ml 
ethanol at 70C forming the oil phase containing solid dispersion (S/O). After 5 minutes, the nanoparticle 
solution was added dropwise under vigorous stirring to 15 ml of heated (70C) solution of 1% (w/v) PVA 
(31–50 kDa) and 1% (w/v) PEG (6 kDa) over 30 minutes to form the emulsion. The emulsion was stirred for 
10 minutes and added gradually using air flow to a cooled aqueous solution of 1% PVA and PEG (25 ml, 2C 
ice bath) to allow the hardening of the lipid matrix. The final suspension was stirred on ice for further 15 
minutes, and the solid lipid -coated [155Tb]THCPSi-SL were separated from the solution by centrifugation. 
Finally [155Tb]THCPSi-SL were sonicated in 0.3% Tween 80 (w/v) for 90 seconds with 5 second pulse every 
30 seconds. Thereafter, the final solution of [155Tb]THCPSi-SL was moved to the next step of RBC membrane 
coating. 
2.3.2 RBC membrane coating 
Whole blood (5.5 mL, withdrawn from five 12-week old Balb/c female mice as will be described in section 
2.5) was diluted with 5.5 mL phosphate-buffered saline (PBS) at pH 7.4. The diluted blood was layered atop 
3 ml of Ficoll-Paque medium in a 15 ml centrifuge tube and centrifuged for 40 minutes at 400g. After the 
centrifugation, the RBCs were collected from the bottom of the centrifuge tube. The RBCs were then 
washed four times with PBS by centrifugation at 4,020g. The final RBC yield was  9 × 105 cells/ml. Then, 
the RBCs were resuspended in 2 mL lysis buffer (20 mM Tris-HCl pH 7.5, 10 mM KCl, 2 mM MgCl2 in milli-Q 
water). After a brief ultrasonication, the solution was centrifuged at 4,020g and the supernatant collected. 
The pellet was resuspended in 2 ml of lysis buffer, centrifuged again at 4,020g, and the supernatant was 
collected and pooled together with the first supernatant. Then, the supernatant was centrifuged at 20,000g 
for 20 min at 4 °C using a TLA 120.2 rotor in an Optima MAX ultracentrifuge (Beckmann Coulter, USA). The 
pellet was discarded and the supernatant was finally centrifuged at 100,000g for 5 min at 4 °C. The 
resulting pellet was re-dispersed in 5.5 ml of milli-Q water.  
The RBC coating procedure was first optimized in terms of the extruder membrane pore diameter using the 










was determined to be optimal, and was used in the RBC coating procedure for the [155Tb]THCPSi and 
[155Tb]THCPSi-SL nanoparticles as follows: 360 µg of either [155Tb]THCPSi or [155Tb]THCPSi-SL in 300 µL of 
0.3%(v/v) Tween 80–1PBS, pH=7.4, was divided into two 1.5-ml microtubes. Then, 500 µL of RBC 
membranes in milli-Q water and 350 µL buffer was added in both the tubes to have a total volume of 2×1 
ml. The 1 ml samples were separately extruded 21 times across a semi-permeable membrane with 400-nm 
pore size (Avanti Polar Lipids, Alabaster, AL, USA) using a mini-extruder with 1 ml syringe volume (Avanti 
Polar Lipids).  The needed number of extrusions was obtained by analyzing TEM images of samples after 
different number of extrusions during the development phase of the extrusion process.  
2.4 In vitro radiolabel stability assay 
For the selection of the optimal nanoparticle design for the in vivo experiment, an in vitro radiolabel 
dissolution test for the particles was carried out. 10 µl, 30 µl and 50 µl of [155Tb]THCPSi, [155Tb]THCPSi-RBC 
and [155Tb]THCPSi-SL-RBC suspensions, respectively, were placed to 50-ml conical polypropylene centrifuge 
tubes with 30 ml of three different solutions:  two phosphate-buffered saline (PBS) solutions with 
physiologically relevant pHs 7.4 and 5.6, and a mixture of 50% pH 7.4 PBS and 50% human plasma (from the 
Finnish Red Cross Blood Service, Helsinki, Finland). All experiments were carried out in triplicate and the 
radioactivity concentration (not NP concentration due to the different specific activity of each nanoparticle 
type) was kept constant across all samples. The vials were incubated at 37˚C under constant shaking. A 450-
µl sample was taken from each vial at 30 min, 1 h, 4 h, 8 h, 20 h, 40 h and 60 h for all samples and 
additional two samples at 156 h and 228 h were taken for the pH 7.4 and pH 5.6 vials. At each sampling, the 
withdrawn sample volume was replaced with respective amount of buffer solution. The samples 
(450 l) were taken into 0.5-ml centrifugal filter devices with a 10-kDa MWCO poly(ethersulfone) (PES) 
membrane (VWR Collection), and the particles were separated from the solution by centrifugation (13,000g 
for 15 minutes). Both particles and solution were measured with Hidex Automatic Gamma Counter (Hidex 
Corporation, Turku, Finland), and the percentage of undissolved activity in particles was calculated, with 










2.5 RBC membrane isolation and in vivo determination of [155Tb]THCPSi-RBC nanoparticle circulation half-
life in mice 
All animal experiments were conducted under the ethical approval of the National Board for Animal 
Experimentation in Finland (license number ESAVI/12132/04.10.07/2017) and in accordance to the 
respective national and European guidelines and policies. 8-week old female Balb/cAnN:Crl mice used in all 
experimental procedures were purchased from Charles River (Scanbur A/S, Karlslunde, Denmark) and 
group-housed in conventional polycarbonate caging on aspen bedding in a HEPA-filtered environmentally 
controlled (temperature 221C, 5510% relative humidity, 12:12 light cycle) housing unit. Rodent chow 
and water were provided ad libitum.  
For red blood cell membrane isolation, the mice were anesthetized with an intraperitoneal injection of 100 
mg/kg of sodium pentobarbital (Mebunat Vet 60 mg/ml, Orion Pharma, Espoo, Finland) and blood was 
collected with cardiac puncture to Na-citrate tubes (Greiner-Bio-One Vacuette Na-Citrate 3.2%, 1 part 
anticoagulant to 5 parts mouse whole blood) and stored on ice until RBC isolation.  
The mice were administered intravenously 9.58 ± 0.08 kBq of [155Tb]THCPSi-RBC nanoparticles in 0.3%(v/v) 
Tween 80–1PBS, pH=7.4 using a 29G insulin syringe, and venous blood samples (10-20 l) were collected 
to weighed 1.5-ml microtubes from the contralateral vein through a temporary cannula at 20 min, 1 h, 2 h 
and 4 h after administration followed by sacrifice with CO2 asphyxiation and blood collection by cardiac 
puncture at 8 h after administration. The radioactivity in the blood samples (from 4–5 mice per time point) 
was measured on a gamma-ray spectrometer, and the results are expressed as percentage of injected dose 
per gram (%ID/g) of blood. 
2.6 Ex vivo biodistribution of [155Tb]THPSi-RBC in mice after intravenous injection  
At 8 hours post injection, the mice (n=5) were euthanized by CO2 asphyxiation and urine, blood and 
selected tissues were collected, weighed and the radioactivity measured using gamma ray spectrometry as 
described below. The results of the biodistribution are expressed as %ID/g of tissue.   










The activities of the organ and blood samples were determined using Hidex Automatic Gamma Counter 
with a 3” well-type NaI crystal. The measurement efficiency was determined using calibration standards 
whose activities were measured using an efficiency calibrated HPGe spectrometer (Ortec GEM-25195-P-S). 
The activities of the 4 and 8-hour blood samples with the smallest activities were re-measured with an 
efficiency calibrated, sensitive Canberra GX8021 Xtra detector (relative efficiency 95.8%) for minimizing the 
detection limit. 
3. Results and discussion 
3.1 Depth profile of implanted radionuclides in PSi 
The experimentally obtained depth profile of 155Dy in a THCPSi film is shown in Figure 1, together with the 
depth profiles simulated with SRIM package. The simulated depth distribution in solid silicon (indicated in 
purple) peaks at roughly 30 nm. The simulated distribution in a silicon with a porosity to 70 % (indicated in 
green) yields a broader distribution peaking at depth of 100 nm, evident also through scaling. The 
experimental profile (indicated in blue) peaks at the same depth but the width does not correspond directly 
to that of the simulated one. This can be understood when considering the structure of a PSi film, shown in 
Figure 2, where the surface and cross-sectional view of a THCPSi foil can be seen.  The particles are 
implanted into a non-uniform, porous surface, allowing the ions randomly either to penetrate deeper in the 
material through a pore or stop faster in the branching solid silicon skeleton. 
3.2 Irradiation post-processing 
The THCPSi films arrived at University of Helsinki a little over four days after the implantation. At this time, 
the activities in the films were measured with at HPGe detector and were about 57 MBq for 155Tb, 2.5 MBq 
for 155Dy and 3.6 MBq for 139Ce. The total mass of the silicon films in the beginning of the process was 17.4 
mg of which 4.4 mg were covered by the 155Dy implanted films and 13 mg by the added inactive film.  The 
activity of 155Tb was followed in all stages of particle processing to gain information on the yields of each 
processing step. The percentages of activity left from the original activity after each processing step are 
shown in Figure 3.  The figure shows also the approximate time spent for each processing step. A major loss 










the initial particle dispersion containing the entire milled batch. As the implanted ions are located mainly in 
the first few layers of the THCPSi film, considerable loss of activity was expected since nanoparticles can be 
formed from the entire thickness of the film. The use of relatively thick porous films however facilitated 
easier and safer mounting and handling of the material at all stages. In the coating processes the yields 
were about 22 % and 18 % for THCPSi-RBC and THCPSi-SL-RBC, respectively. Considering this, the final yield 
of the process, without the split of the activity before the coating procedures to two batches, would be of 
the order of 1.2–1.5 % from the original implanted activity. For this reason, further effort must be made for 
optimizing the particle processing in order to obtain a higher number of particles of the desired size 
distribution and minimize loss of the radioactivity. It can also be estimated that due to the relatively large 
amount of inactive THCPSi film added to the process, only about 0.5% of the produced nanoparticles had a 
radioactive label.  Nevertheless, the particle number and activity obtained were satisfactory for going 
forward with the biological evaluation. 
Characterization of the porous structure was done with the non-radioactive reference nanoparticles, which 
showed the specific surface area being approximately 2423 m2/g with a total pore volume of 0.730.02 
cm3/g. These correspond to an average pore diameter of circa 12 nm assuming the pores to be cylindrical. 
The size and surface properties of the nanoparticles were followed over the coating processes. Table 1 
shows the progressive change in the particle size from approximately 160 nm to 200–360 nm determined 
by dynamic light scattering (DLS) and surface zeta potential after the coatings using the inactive reference 
THCPSi-RBC and THCPSi-SL-RBC nanoparticles. 
A high-angle annular dark-field image of a bare THCPSi nanoparticle and a TEM image of an inactive RBC-
THCPSi reference particle are shown in Figure 4. The RBC membrane does cover the THCPSi particle only 
partly. The patchy appearance of the RBC membrane coating is likely due to the preferential arrangement 
of the RBC membrane on the hydrophobic THCPSi surface with the lipophilic layer facing the nanoparticle 
minimizing the surface water layer between the particle and the membrane.  Nevertheless, the coverage 
was sufficient to improve the stability of the nanoparticle dispersion in physiological media. 










The in vitro radiolabel dissolution test results are shown in Figures 5 a–c.  The radiolabel stability on the 
particles in physiological media was followed up to 9.5 days.  There are no dramatic differences between 
the radiolabel dissolution properties of the different particles.  About 20% of the radioactivity is released 
until the 60 hours measurement point with all the particles in all the solutions.  In general, the layers of 
coating seem to improve the stability of the particles. This can be seen especially in the bare buffer 
solutions. The particles in plasma were followed up to 60 h and no significant differences between the 
dissolution of the free radiolabel from the different particle types were observed. Since 10-kDa filters were 
utilized for separation of the particles from plasma, it cannot be completely ruled out that the larger 
plasma proteins together with possible protein bound radiometals could have been filtered out together 
with the particles. Regardless of the coating type, the dissolution results in plasma are in good accordance 
with the results in buffer solutions, indicating minor contribution of the possible plasma protein binding to 
the results. Since no significant differences were seen between the THCPSi-RBC and THCPSi-SL-RBC 
nanoparticles in the in vitro radiolabel stability assay, we decided to omit the solid lipid coating and use the 
[155Tb]THCPSi-RBC particles in the in vivo studies. The omission of the solid lipid coating step allowed us to 
attain higher specific activity (based on the decrease in processing time) as well as smaller size for the 
injected nanoparticles. The specific activity of the final formulation of [155Tb]THCPSi-RBC used in the 
intravenous injections was 46.6±0.6 kBq/g. 
3.4 In vivo studies: circulation half-life and biodistribution after intravenous delivery 
The [155Tb]THCPSi-RBC nanoparticles were well tolerated after a single intravenous administration to 
female Balb/c mice. The percentage of the injected dose per gram remaining in the blood at given time 
points is presented in Figure 6. The RBC membrane coating significantly prolonged the circulation half-life 
(tc,1/2) of THCPSi nanoparticles (t1/2 = 42 ± 5 min) when compared to both uncoated 
18F-radiolabeled THCPSi 
[54] and THCPSi-SL[53] nanoparticles (both exhibiting a blood half-life of < 5 minutes). The prolonged 
persistence of the [155Tb]THCPSi-RBC particles in circulation demonstrates that the RBC membrane coating 










the organs of the reticulo-endothelial system (RES), the liver and spleen[55]. Interestingly, the circulating 
nanoparticles could also be subject to selective uptake by the circulating Ly-6Chigh monocytes as has been 
shown to other nanomaterials[56], and this could be further investigated as a strategy towards efficient 
tumor targeting. As non-tumor-bearing mice were used in the pilot study reported herein, the degree of 
tumor accumulation was not studied.  
The ex vivo biodistribution after intravenous administration showed pronounced accumulation of 
[155Tb]THCPSi-RBC to the spleen and the liver (Figure 7), with slightly elevated radioactivity levels present in 
the lung (3.8 %ID/g) and gall bladder (7.9 %ID/g). The interendothelial slits (IES) in the spleen are 
responsible for the mechanical removal of erythrocytes at the end of their normal lifespan of 
approximately 120 d, by which the aged, deformed or rigid cells are not able to fit through the narrow gaps 
in the IES anymore [57, 58]. Consequently, it is unsurprising that the RBC membranes harboring a rigid, 
approximately 200-nm THCPSi nanoparticle are retained in the spleen. This could be avoided by further 
selecting a THCPSi fraction of less than 100 nm in diameter for future studies, but it might be challenging to 
achieve using the top-down production method described. The liver, in turn, removes nanomaterials from 
the body by the activity of the tissue-resident macrophages, and additionally recycles the iron from 
disposed erythrocytes [59]. Therefore, nanoparticle accumulation to the liver was also expected. The 
slightly elevated radioactivity in the gall bladder might result from the degradation of the [155Tb]THCPSi-RBC 
in the liver and subsequent release of 155Tb, but the radioactive species was not characterized further at 
this time. Accumulation of radioactivity to the lung and bone (collected with bone marrow) can likely be 
attributed to nanoparticle aggregation and physical retention in the lung capillaries, and uptake of released 
155Tb – a trivalent cation – to the bone [60], respectively.  In a clinical setting the 155Tb release and 
consecutive bone accumulation would be high with respect to collateral dose to bone marrow.  Therefore, 
methods for improved coating of the particles for the persistence of the radioactive label need to be 










4. Conclusions  
We have demonstrated using 155Tb RIB-implanted porous silicon nanoparticles coated with mouse RBC 
membranes the feasibility of using such theranostic nanosystem for the delivery of RIB based radionuclides 
for radiotherapy with prolonged circulation time. Furthermore, the capability to deliver poorly soluble and 
sensitive pharmaceutical payloads such as chemotherapeutics and radiosensitizers when trapped in the 
porous network of PSi opens an interesting avenue for the development of synergistic radiotherapeutic and 
chemotherapeutic drug delivery systems in the future. Future studies should concentrate on further 
reducing and refining the size distribution of the nanoparticles obtained, the recovery of the radiolabeled 
nanoparticles to maximize the specific activity, and translation of the promising nanosystem to therapeutic 
studies in preclinical cancer models with other RIB based therapeutic isotopes (e.g. those of the Tb 
theranostic quadruplet) and tumor-targeting moieties attached to the RBC membrane coating.   
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SL Solid lipid 
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Figure 1. Experimental depth profile of 155Dy in THCPSi (blue dots). Simulated depth in solid silicon is 
depicted in purple and in silicon with 70 % porosity in green. 
Figure 2. A scanning electron microscope picture of the structure of a THCPSi film. a) Plan view of the pore 
openings in the surface of the film. b) Cross-section view of the porous silicon multilayer structure showing 
the alternating low and high porosity regions. 
Figure 3. Processing yields and the time line in the preparation of coated THCPSi nanoparticles from 155Tb-
implanted THCPSi films.  The main loss of radioactivity in the process is during the selection of the 
appropriately sized fraction of the nanoparticles. 
Figure 4.  Micrsocopic images of THCPSi nanoparticles before and after RBC membrane coating.  a) High-
angle annular dark-field image of a THCPSi nanoparticle b) A representative high-resolution TEM image of a 
THCPSi-RBC particle showing the RBC membrane layer on the hydrophobic THCPSi surface. 
Figure 5. Results of the in vitro dissolution study. The activity remaining in the particles as a function of the 
incubation time in a) 50 % of human plasma and 50 % PBS buffer solution of pH 7.4, b) in PBS buffer 
solution with pH 5.6 and c) in PBS buffer solution with pH 7.4. The samples in plasma were followed up to 
60 h and the samples in the buffer solutions up to 228 h. The time point of 84 hours is excluded from part 
of the samples due to an error in the sampling. 
Figure 6. The measured activity concentrations (%ID/g) in blood as a function of time. The activity 
concentration is calculated as an average ± SD from the samples of 4–5 mice.  The uncertainties are not 
visible in 3rd and 4th data points are since they are smaller than the marker.   The last point (t = 480 min) 
represents the highest possible value  of the the average activity at that time point since of one of the 
samples was already below the minimum detectable activity of the measurement (MDA), and the MDA was 
used in calculating the average activity. The dashed line is an exponential decay function fitted to the 
experimental data, resulting in the blood circulation half-life (tc,1/2). 
Figure 7. Ex vivo biodistribution of [155Tb]THCPSi-RBC nanoparticles 8 hours after a single intravenous 
injection (9.5 kBq) in Balb/c mice shows a pronounced accumulation of the nanoparticles to the spleen 

















PdI ζ-potential (mV) 
THCPSi - 163 ± 2  0.13 ± 0.02 - 19 ± 0.5 
THCPSi-RBC 400 194 ± 1 0.10 ± 0.01 -10.1 ± 0.7 
THCPSi-RBC 800 217 ± 3 0.12 ± 0.01 -9.8 ± 0.3 
THCPSi-SL-RBC 400 282 ± 2 0.24 ± 0.01 -16.9 ± 0.4 
THCPSi-SL-RBC 800 360 ± 2 0.32 ± 0.04 -21.4 ± 1.1 
 
Table 1. The hydrodynamic diameter, polydispersity index (PdI) and zeta-potential for non-radioactive 
THCPSi, THCPSi-RBC and THCPSi-SL-RBC particles prepared using semi-permeable membranes with 400-nm 
and 800-nm pore diameters in the extrusion procedure. The values denote the average ± SD of triplicate 
measurements.  The 400-nm semi-permeable membrane was chosen for the [155Tb]THCPSi-RBC nanoparticle 
fabrication due to the smaller particle size and lower polydispersity index achieved. 
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